Clinical trial
PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS…
NCT00087633 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00087633 |
|---|---|
| Title | PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. |
| Official title | A Randomized, Open-label Study of Prophylactic Administration of PEGASYS Plus Ribavirin After Liver Transplantation on Hepatitis C Recurrence in Patients With Hepatitis C |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | peginterferon alfa-2a [Pegasys], Copegus |
| Enrollment | 115 |
| Start date | Oct 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jul 14, 2004 |
| Last update posted | Mar 29, 2018 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: